The value of pharmaceutical representative visits and medication samples in community-based family practices

Elisabeth L Backer, J. A. Lebsack, R. J N Van Tonder, B. F. Crabtree

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND: Interactions between the pharmaceutical industry and physicians have been discussed in numerous publications; however, most articles are limited to surveys and self-report data and often focus on academic or training contexts. We describe the role of pharmaceutical representatives and the use of samples in community-based family practices, using data obtained by directly observing clinical encounters. METHODS: We collected detailed descriptive field notes of the direct observations of 53 primary care clinicians and 1588 patient encounters in 18 purposefully selected Nebraska family practices. We used a comparative case study design, that used depth interviews of clinicians and office staff, and included details of the interactions with pharmaceutical representatives and the use of samples in clinical encounters. RESULTS: Individual providers and practices displayed noticeable variation in their approaches to drug representatives and samples. We found formal strategies and policies in a minority of practices. Generally there was little structure in the organization and distribution of sample medications at the office level, and detailed patient education regarding these drags was rarely observed in patient encounters. Nevertheless, samples were used in almost 20% of observed encounters, at times as starter dosages, but often as complete courses of treatment. The benefits derived from contact with the pharmaceutical industry varied substantially, but most often included free medication samples, meals, and patient education materials. CONCLUSIONS: Clinicians have a complex symbiosis with the pharmaceutical industry and need to critically evaluate their handling of samples and their contact with pharmaceutical representatives to optimize this relationship and ensure quality patient care. Clinics with specific policies for interactions with drug companies appear to derive more satisfaction from their encounters.

Original languageEnglish (US)
Pages (from-to)811-816
Number of pages6
JournalJournal of Family Practice
Volume49
Issue number9
StatePublished - Jan 1 2000

Fingerprint

Family Practice
Drug Industry
Patient Education
Pharmaceutical Preparations
Symbiosis
Quality of Health Care
Drug Interactions
Self Report
Meals
Publications
Primary Health Care
Patient Care
Teaching
Organizations
Interviews
Physicians
Therapeutics

Keywords

  • Medication samples [non-MESH]
  • Pharmaceutical representatives [non-MESH]
  • Role

ASJC Scopus subject areas

  • Family Practice

Cite this

The value of pharmaceutical representative visits and medication samples in community-based family practices. / Backer, Elisabeth L; Lebsack, J. A.; Van Tonder, R. J N; Crabtree, B. F.

In: Journal of Family Practice, Vol. 49, No. 9, 01.01.2000, p. 811-816.

Research output: Contribution to journalArticle

Backer, Elisabeth L ; Lebsack, J. A. ; Van Tonder, R. J N ; Crabtree, B. F. / The value of pharmaceutical representative visits and medication samples in community-based family practices. In: Journal of Family Practice. 2000 ; Vol. 49, No. 9. pp. 811-816.
@article{9447d62c59564e35a4d6f0336b0c9306,
title = "The value of pharmaceutical representative visits and medication samples in community-based family practices",
abstract = "BACKGROUND: Interactions between the pharmaceutical industry and physicians have been discussed in numerous publications; however, most articles are limited to surveys and self-report data and often focus on academic or training contexts. We describe the role of pharmaceutical representatives and the use of samples in community-based family practices, using data obtained by directly observing clinical encounters. METHODS: We collected detailed descriptive field notes of the direct observations of 53 primary care clinicians and 1588 patient encounters in 18 purposefully selected Nebraska family practices. We used a comparative case study design, that used depth interviews of clinicians and office staff, and included details of the interactions with pharmaceutical representatives and the use of samples in clinical encounters. RESULTS: Individual providers and practices displayed noticeable variation in their approaches to drug representatives and samples. We found formal strategies and policies in a minority of practices. Generally there was little structure in the organization and distribution of sample medications at the office level, and detailed patient education regarding these drags was rarely observed in patient encounters. Nevertheless, samples were used in almost 20{\%} of observed encounters, at times as starter dosages, but often as complete courses of treatment. The benefits derived from contact with the pharmaceutical industry varied substantially, but most often included free medication samples, meals, and patient education materials. CONCLUSIONS: Clinicians have a complex symbiosis with the pharmaceutical industry and need to critically evaluate their handling of samples and their contact with pharmaceutical representatives to optimize this relationship and ensure quality patient care. Clinics with specific policies for interactions with drug companies appear to derive more satisfaction from their encounters.",
keywords = "Medication samples [non-MESH], Pharmaceutical representatives [non-MESH], Role",
author = "Backer, {Elisabeth L} and Lebsack, {J. A.} and {Van Tonder}, {R. J N} and Crabtree, {B. F.}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "49",
pages = "811--816",
journal = "Journal of Family Practice",
issn = "0094-3509",
publisher = "Appleton-Century-Crofts",
number = "9",

}

TY - JOUR

T1 - The value of pharmaceutical representative visits and medication samples in community-based family practices

AU - Backer, Elisabeth L

AU - Lebsack, J. A.

AU - Van Tonder, R. J N

AU - Crabtree, B. F.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - BACKGROUND: Interactions between the pharmaceutical industry and physicians have been discussed in numerous publications; however, most articles are limited to surveys and self-report data and often focus on academic or training contexts. We describe the role of pharmaceutical representatives and the use of samples in community-based family practices, using data obtained by directly observing clinical encounters. METHODS: We collected detailed descriptive field notes of the direct observations of 53 primary care clinicians and 1588 patient encounters in 18 purposefully selected Nebraska family practices. We used a comparative case study design, that used depth interviews of clinicians and office staff, and included details of the interactions with pharmaceutical representatives and the use of samples in clinical encounters. RESULTS: Individual providers and practices displayed noticeable variation in their approaches to drug representatives and samples. We found formal strategies and policies in a minority of practices. Generally there was little structure in the organization and distribution of sample medications at the office level, and detailed patient education regarding these drags was rarely observed in patient encounters. Nevertheless, samples were used in almost 20% of observed encounters, at times as starter dosages, but often as complete courses of treatment. The benefits derived from contact with the pharmaceutical industry varied substantially, but most often included free medication samples, meals, and patient education materials. CONCLUSIONS: Clinicians have a complex symbiosis with the pharmaceutical industry and need to critically evaluate their handling of samples and their contact with pharmaceutical representatives to optimize this relationship and ensure quality patient care. Clinics with specific policies for interactions with drug companies appear to derive more satisfaction from their encounters.

AB - BACKGROUND: Interactions between the pharmaceutical industry and physicians have been discussed in numerous publications; however, most articles are limited to surveys and self-report data and often focus on academic or training contexts. We describe the role of pharmaceutical representatives and the use of samples in community-based family practices, using data obtained by directly observing clinical encounters. METHODS: We collected detailed descriptive field notes of the direct observations of 53 primary care clinicians and 1588 patient encounters in 18 purposefully selected Nebraska family practices. We used a comparative case study design, that used depth interviews of clinicians and office staff, and included details of the interactions with pharmaceutical representatives and the use of samples in clinical encounters. RESULTS: Individual providers and practices displayed noticeable variation in their approaches to drug representatives and samples. We found formal strategies and policies in a minority of practices. Generally there was little structure in the organization and distribution of sample medications at the office level, and detailed patient education regarding these drags was rarely observed in patient encounters. Nevertheless, samples were used in almost 20% of observed encounters, at times as starter dosages, but often as complete courses of treatment. The benefits derived from contact with the pharmaceutical industry varied substantially, but most often included free medication samples, meals, and patient education materials. CONCLUSIONS: Clinicians have a complex symbiosis with the pharmaceutical industry and need to critically evaluate their handling of samples and their contact with pharmaceutical representatives to optimize this relationship and ensure quality patient care. Clinics with specific policies for interactions with drug companies appear to derive more satisfaction from their encounters.

KW - Medication samples [non-MESH]

KW - Pharmaceutical representatives [non-MESH]

KW - Role

UR - http://www.scopus.com/inward/record.url?scp=0033772053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033772053&partnerID=8YFLogxK

M3 - Article

C2 - 11032205

AN - SCOPUS:0033772053

VL - 49

SP - 811

EP - 816

JO - Journal of Family Practice

JF - Journal of Family Practice

SN - 0094-3509

IS - 9

ER -